Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.
Financial Results:
Sanofi India Ltd reported Revenues for Q1FY25 of ₹464.00 Crores down from ₹515.00 Crore year on year, a fall of 9.9%.
Total Expenses for Q1FY25 of ₹357.00 Crores down from ₹403.00 Crores year on year, a fall of 11.41%.
Consolidated Net Profit of ₹103.00 Crores down 16.26% from ₹123.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹44.96, down 15.85% from ₹53.43 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.